SPOTLIGHT -
Available Treatment Options for Chemotherapy-Naïve mCRPC
Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
Mutations in HRR-Related Genes in Prostate Cancer
A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.
The Utility of Genetic Testing in Patients with Prostate Cancer
An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.
Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression
Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.
Case Presentation: A 64-Year-Old Man with Metastatic Prostate Cancer
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.
Patient Profile 6: Robotic Radical Prostatectomy for Adenocarcinoma
Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.
Patient Profile 5: IMRT for Adenocarcinoma
Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.
Prostate Cancer Imaging: the CONDOR Trial
Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.
Patient Profile 4: Recurrent Prostate Cancer
Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.
Bone Scans for Prostate Cancer Imaging
A panel of experts review whether bone scans still have a place in prostate cancer imaging.
Patient Profile 3: High-Risk Prostate Cancer
Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.
Patient Profile 2: High-Risk Prostate Cancer
Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.
The Role for PSMA PET Imaging in Prostate Cancer Monitoring
A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.
Discussing Treatments with Patients Based on Prostate Cancer Imaging
A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.
Visual Analysis vs SUV for Prostate Cancer Imaging
Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.
Key Messages from the OSPREY Trial
Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.
Prostate Cancer Imaging: the OSPREY Trial
Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.
Patient Profile 1: High-Risk Localized Prostate Cancer
Doctors present the patient profile of a 66-year-old man with high-risk localized prostate cancer.
The Learning Curve of PSMA PET Scans
Michael Gorin, MD, describes his experiences with prostate cancer imaging both in academia and community-based practices.
The Multidisciplinary Approach to Prostate Cancer Management
An explanation of the importance of clinical providers following a multidisciplinary approach for prostate cancer management.
PSMA PET Clinical Trials
Experts review ongoing clinical trials in PSMA PET technology.
PSMA PET Scans for Prostate Cancer Imaging
The panel explains the science behind PSMA PET scans and reviews the different positron-emitters used in the scans.
Rapid Advances in Prostate Cancer Imaging
A background on the available options and recent advances in prostate cancer imaging.
Future Directions for the Management of Advanced Prostate Cancer
Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Role of PSMA PET in Advanced Prostate Cancer Management
Experts in prostate cancer review the role of PSMA PET imaging in advanced prostate cancer and its impact on disease management.
Managing AEs for ARI Therapy in Advanced Prostate Cancer
Bobby Liaw, MD, and Vivek K. Narayan, MD, MS, share clinical pearls for the management of adverse events from ARI-directed therapy in advanced prostate cancer.
Role of PSA Kinetics in nmCRPC Management
Ashley E. Ross, MD, PhD, comments on the clinical significance of PSA response in patients with nmCRPC.
Phase 3 SPARTAN Trial in nmCRPC
Vivek K. Narayan, MD, MS, reviews data from the SPARTAN trial in nmCRPC and discusses the importance of assessing health-related quality of life.
PROSPER and ARAMIS Trials in nmCRPC
Ashley E. Ross, MD, PhD, discusses challenges and unmet needs in managing nmCRPC and Bobby Liaw, MD, reviews the PROSPER and ARAMIS trials.
Approaching Treatment of mCSPC
Vivek K. Narayan, MD, MS, shares thoughts on approaching treatment selection of mCSPC and Ashley E. Ross, MD, PhD, comments on the use of relugolix in patients.